Evaluation of the performance of an ophthalmic thermosensitive hydrogel containing combination of Suramin and Bevacizumab

QUINTEROS DANIELA; LOPEZ SEBASTIÁN; SILVA-COUTO JUAN; MALLETTO BELKYS; ALLEMANDI DANIEL; PALMA SANTIAGO; GALLO JUAN

CURRENT PHARMACEUTICAL DESIGN.

BENTHAM SCIENCE PUBL LTD

Lugar: Oak Park; Año: 2016 vol. 22 p. 1 - 9

1381-6128

In the present work, we report the results of studies concerning the formulation, characterization and anti-angiogensis effect in an induced corneal neovascularization in rats of suramab (SUM), vehiculised into a poloxamer thermosensitive hydrogel. SUM is a new pharmaceutical combination made up of suramine (SUR) and bevacizumab (BVM), which showed a high synergistic effect when administered jointly. As pharmaceutical vehicle, poloxamer aqueous dispersions were used since this systems is able to maintain fluidity at low temperature (37ºC). The formulations were characterized using rheological, biopharmaceutical (drug release) and morphological (SEM) techniques were also addressed. The rheological behavior was influenced by the addition of drugs resulting in the decrease of gelation temperature (Tgel). Both drugs were released from poloxamer gels by mean of an anomalous mechanism. However, BVM was released faster than SUR, and the combination of them (SUM) seem to diminish the delivery probably owed to some kind of interactions between them and/or with the polymeric matrix. The preliminary in vivo studies showed that SUM-poloxamer gel is able to increase the antiangiogenic effect, comparatively to SUM solution. Besides, no injurious effect was observed in histological tissue examination after administration.